Shots:

• Celsius to receive payments and milestones based on the use of biomarkers identified- holding the rights to integrate the data generated from the study into its database of patient and single-cell genomic information further interrogating it for its own target and drug discovery
• Janssen to utilize Celsius’ single-cell genomics and machine learning platformto identify response biomarkers from P-II VEGA study assessing guselkumab and golimumab in patients with UC
• Celsius and Janssen will extract deep molecular and cellular insights from the generated data- leading to better QoL. Guselkumab (marketed as Tremfya) is a mAb indicated for plaque psoriasis whereas Golimumab (marketed as Simponi) is a TNF inhibitor indicated for UC

Click here to read full press release/ article

Ref: Celsius Therapeutics | Image: Janssen